Back to Search Start Over

1119 - FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC).

Authors :
Necchi, A.
Castellano, D.
Mellado, B.
Pang, S.T.
Urun, Y.
Park, S.H.
Vaishampayan, U.
Currie, G.
Abella, E.
Pal, S.
Source :
European Urology Supplements. Mar2019, Vol. 18 Issue 1, pe1513-e1513. 1p.
Publication Year :
2019

Subjects

Subjects :
*SALVAGE therapy
*CARCINOMA

Details

Language :
English
ISSN :
15699056
Volume :
18
Issue :
1
Database :
Academic Search Index
Journal :
European Urology Supplements
Publication Type :
Academic Journal
Accession number :
135600691
Full Text :
https://doi.org/10.1016/S1569-9056(19)31090-5